MATRIX METALLOPROTEINASES AND THEIR TISSUE INHIBITORSIN OVARIAN CANCER CLINICAL COURSE AND PROGNOSIS

Publications devoted to the role of various representatives of matrix metalloproteinases (MMPs) family and their tissue inhibitors in
ovarian cancer in differential diagnostics, prognosis and in the development of new treatment modalities are critically analyzed in this
review. It is concluded that gelatinases/collagen IV collagenases – MMP-9 and MMP-2, matrilysin (MMP-7), type 1 tissue MMP inhibitor
(TIMP-1) and membrane-type MMP-1 can be considered as the most perspective markers for differential diagnostics and ovarian cancer
prognosis. Existing methods of suppression of MMPs activity including application of specific inhibitors permit to reduce ovarian cancer cells
invasiveness in vitro, but need further refinement for introduction into clinical practice.

E.S. Gershtein (1), D.N. Kushlinsky (2), L.V. Adamyan (2), I.V. Tereshkina (1), K.P. Laktionov (1)
1 -N.N. Blokhin Russian Cancer Research Center, Moscow
2 -Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Moscow